What are the latest advancements in acute myeloid leukemia therapy?

Future Oncol. 2017 Apr;13(10):867-871. doi: 10.2217/fon-2016-0555. Epub 2017 Feb 27.

Authors

Aaron Goodman^{1

2}, Edward D Ball¹

Affiliations

¹ Department of Medicine, Division of Blood & Marrow Transplantation, University of California, San Diego Moores Cancer Center, San Diego, CA, USA.
² Department of Medicine, Division of Hematology/Oncology, University of California, San Diego Moores Cancer Center, San Diego, CA, USA.

PMID: 28266249
DOI: 10.2217/fon-2016-0555

No abstract available

Keywords: AML; antibody–drug conjugates; targeted agents; therapy.

MeSH terms

Aged
Aged, 80 and over
Deoxycytosine Nucleotides / chemistry
Deoxycytosine Nucleotides / therapeutic use
Humans
Immunoconjugates / therapeutic use*
Immunotherapy*
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / pathology
Molecular Targeted Therapy
Small Molecule Libraries / therapeutic use*
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
fms-Like Tyrosine Kinase 3 / immunology
fms-Like Tyrosine Kinase 3 / therapeutic use

Substances

Deoxycytosine Nucleotides
Immunoconjugates
Small Molecule Libraries
FLT3 protein, human
fms-Like Tyrosine Kinase 3